Jidinum

Sitagliptin, the active ingredient in Jidinum, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for systemic use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to improve blood glucose control when used with diet and exercise.

GNH USA supplies Jidinum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and providing reliable logistics for global distribution, and the firm’s network ensures timely delivery and regulatory compliance across multiple regions.

Sitagliptin, marketed as Jidinum, is a DPP‑4 inhibitor used in the management of type 2 diabetes and related therapeutic pathways. - Type 2 diabetes mellitus: improves glycemic control as monotherapy or in combination with other antidiabetic agents. - Adjunct to metformin therapy: provides additional HbA1c reduction when metformin alone does not achieve target levels. - Combination with insulin: helps lower post‑prandial glucose excursions in patients requiring insulin supplementation.

Sitagliptin may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nasopharyngitis: inflammation of the nasal passages and throat. - Headache: mild to moderate head pain. - Upper respiratory tract infection: symptoms such as cough and congestion. - Nausea: feeling of stomach upset.

Serious or Rare Side Effects: - Pancreatitis: inflammation of the pancreas, presenting with severe abdominal pain. - Severe allergic reactions: including rash, angioedema, or anaphylaxis. - Joint pain: unexplained arthralgia. - Bullous pemphigoid: rare skin blistering disorder.

When prescribing Jidinum, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: assess kidney function and adjust dose if necessary. - History of pancreatitis: use with caution and monitor for abdominal symptoms. - Hypersensitivity: discontinue immediately if allergic reactions occur. - Elderly patients: monitor for increased incidence of adverse effects. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Sitagliptin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase sitagliptin plasma levels. - Co‑administration with insulin secretagogues (e.g., sulfonylureas): heightened risk of hypoglycaemia. - Rifampin therapy: may reduce sitagliptin effectiveness.

Moderate Interactions (Monitor Closely): - ACE inhibitors: monitor renal function and potassium levels. - Diuretics: observe for changes in blood pressure and electrolytes. - Warfarin: check INR periodically for anticoagulation stability.